Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.

Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Publication: 2021- : [New York] : Elsevier
Original Publication: New York, Grune & Stratton [etc.]

Neoplasms, Second Primary*/etiology ; Neoplasms, Second Primary*/therapy ; Neoplasms, Second Primary*/epidemiology ; United States Food and Drug Administration* ; Immunotherapy, Adoptive*/adverse effects ; Adverse Drug Reaction Reporting Systems*; Humans ; United States/epidemiology ; Male ; Receptors, Chimeric Antigen/immunology ; Female ; Middle Aged ; Adult ; Aged

Abstract: Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.
(© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Date Created: 20240314 Date Completed: 20240516 Latest Revision: 20240516

20240516

10.1182/blood.2024024166

38483155